Downstream processing of proteins from mammalian cells.

Area of Science:

• Biotechnology
• Biopharmaceutical Manufacturing
• Cell Line Development

Background:

• Continuous mammalian cell lines were initially limited to research applications.
• Safety concerns regarding transformed cells hindered their use in therapeutic protein production.
• Mammalian expression systems offer distinct advantages over bacterial systems for complex protein manufacturing.

Purpose of the Study:

• To evaluate the feasibility and safety of using continuous mammalian cell lines for therapeutic protein production.
• To highlight the multidisciplinary efforts in addressing safety concerns associated with mammalian cell lines.
• To showcase the successful integration of mammalian cell culture in biopharmaceutical manufacturing.

Main Methods:

• Development and validation of safety protocols for transformed mammalian cell lines.
• Comparative analysis of protein production yields and quality between mammalian, bacterial, and yeast systems.
• Clinical evaluation of therapeutic proteins produced using mammalian cell culture technology.

Main Results:

• Seven recombinant human therapeutics have received FDA approval, with nearly half produced in mammalian cells.
• Mammalian cell-derived products include OKT3, tissue plasminogen activator (t-PA), and erythropoietin (EPO).
• Over a dozen additional recombinant cell culture products are in advanced clinical trials.

Conclusions:

• Continuous mammalian cell lines have transitioned from research tools to viable platforms for biopharmaceutical production.
• The successful market introduction and clinical progression of mammalian cell-derived therapeutics validate their safety and efficacy.
• Mammalian cell lines are poised to become the preferred hosts for a wide range of future biotechnology products.